Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Efficacy Differences Within Drug Classes Unsupported By Data, FDA's Temple Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Studies that look for differences in efficacy among members of the same drug class are only performed when necessary for approval, CDER Office of Medical Policy Director Temple tells DIA. While questioning the introduction of "follow-on" compounds, Temple also highlights AstraZeneca's success in achieving a more optimal dose for Nexium.

You may also be interested in...



Follow-On Brand Drugs Could Draw FTC Anticompetitive Scrutiny

Introduction of certain types of successor drugs as the original product nears patent expiration has "caught the attention" of individuals at FTC, Commissioner Harbour tells BIO annual conference. A company's history and methods of engaging in this practice to blunt generic competition could open it up to agency scrutiny, she says.

Bextra Pulled From Market, But Pfizer Hopes To Explore Other Options

Pfizer is characterizing FDA's request for a withdrawal of Bextra as a "marketing suspension"; the company hopes to continue discussions on how valdecoxib could re-enter the market. Increased cardiovascular risk plus a "special risk" of serious skin reactions led FDA to recommend pulling the COX-2 inhibitor.

COX-2 Cardio Risk Is Class Effect, But Varies By Drug And Dose, Cmte. Says

While a COX-2 class signal is likely, several committee members suggest data are not conclusive enough to make a "global" statement on the class. Voting FDA consultant Nissen recommends FDA explore whether COX-2 inhibition plays a role in hypertension, thereby contributing to an increased cardiovascular risk.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel